Lars Anders
Impact in
- Hematology top 5%
- Multiple Myeloma Research and Treatments
- Cancer Research top 5%
Papers in
- Oncology 8
- Cancer-related Molecular Pathways 6
-
- Advanced Breast Cancer Therapies 6
- Co-authors
- Yoojin Choi (1 shared paper)Richard A. Young (3 shared papers)Piotr Siciński (3 shared papers)Per Hydbring (2 shared papers)Yoon Jong Choi (2 shared papers)Joel M. Chick (1 shared paper)Nan Rosemary Ke (1 shared paper)Stephen P. Hunger (1 shared paper)
- Journals
- Cancer Cell (3 papers)Nature (2 papers)Nutrition Journal (1 paper)Science (1 paper)Molecular and Cellular Biology (1 paper)
- Partner nations
- United StatesUnited KingdomGermany
In The Last Decade
Lars Anders
16 papers receiving 2.7k citations
Lars Anders's Hit Papers
Peers
Comparison fields: 5 of 92
- Hematology 317
- Cancer Research 391
- Molecular Biology 1.9k
- Oncology 645
- Pulmonary and Respiratory Medicine 381
Countries citing papers authored by Lars Anders
This map shows the geographic impact of Lars Anders's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lars Anders with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lars Anders more than expected).
Fields of papers citing papers by Lars Anders
This network shows the impact of papers produced by Lars Anders. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lars Anders. The network helps show where Lars Anders may publish in the future.
Co-authors
The 25 scholars most cited alongside Lars Anders, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element Hit paper breakdown → | 2014 | 629 |
| 2 | Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer Hit paper breakdown → | 2016 | 535 |
| 3 | 2011 | 465 | |
| 4 | 2015 | 252 | |
| 5 | 2013 | 245 | |
| 6 | 2013 | 154 | |
| 7 | 2006 | 90 | |
| 8 | 2017 | 87 | |
| 9 | 2020 | 83 | |
| 10 | 2014 | 51 | |
| 11 | 2023 | 48 | |
| 12 | CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety Hit paper breakdown → | 2025 | 42 |
| 13 | 2018 | 27 | |
| 14 | 2014 | 24 | |
| 15 | 2025 | 4 | |
| 16 | 2024 | 1 | |
| 17 | 2025 | 0 |
About Lars Anders
Lars Anders is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Cancer Research and Genetics, having authored 17 papers that have together received 2.7k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (6 papers), Advanced Breast Cancer Therapies (6 papers), Protein Degradation and Inhibitors (4 papers), Genomics and Chromatin Dynamics (3 papers), RNA modifications and cancer (2 papers), Microtubule and mitosis dynamics (2 papers), Chronic Lymphocytic Leukemia Research (2 papers) and Cancer, Hypoxia, and Metabolism (2 papers). The work is most often cited by research in Hematology (317 citations), Cancer Research (391 citations), Molecular Biology (1.9k citations), Oncology (645 citations) and Pulmonary and Respiratory Medicine (381 citations). Lars Anders has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Yoojin Choi, Richard A. Young, Piotr Siciński, Per Hydbring, Yoon Jong Choi, Joel M. Chick, Nan Rosemary Ke, Stephen P. Hunger, Alla Berezovskaya and A. Thomas Look. Their work appears in journals such as Cancer Cell, Nature, Nutrition Journal, Science and Molecular and Cellular Biology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.